Delivery Order SPE2DB24D2105-SPE2DB25FAQCU
- Not listed
- The Defense Logistics Agency (DLA) awarded a delivery order to AmerisourceBergen Drug Corp for RINVOQ ER 15 MG tablets (30-count units) valued at $9,780.29 under a firm fixed-price contract type. The award, made on August 19, 2025, with an ultimate completion date of August 20, 2025, represents a non-set-aside competitive procurement. AmerisourceBergen Drug Corp, a major pharmaceutical distributor headquartered in Conshohocken, Pennsylvania, will perform this delivery order from its corporate...
- The Defense Logistics Agency (DLA) awarded a delivery order valued at $6,223.32 to AmerisourceBergen Drug Corp for RINVOQ ER 30 mg tablets (30-count unit dose packages) on August 15, 2025, with an ultimate completion date of August 18, 2025. This firm fixed price delivery order represents a non-competitive, non-set-aside procurement and will be performed at the contractor's facility in Conshohocken, Pennsylvania. The award is issued under AmerisourceBergen's existing Indefinite Delivery Contract...
- The Defense Logistics Agency (DLA) awarded a delivery order valued at $33,525.88 to AmerisourceBergen Drug Corp for RINVOQ ER 15 mg tablets (30-count units) on July 22, 2025, with completion scheduled for July 23, 2025. This firm fixed-price delivery order represents a competitive award with no set-aside designation. AmerisourceBergen Drug Corp, a major pharmaceutical distributor headquartered in Conshohocken, Pennsylvania, will perform the work at its corporate office location. The delivery...
- The Defense Logistics Agency (DLA) awarded a delivery order valued at $18,524.84 to AmerisourceBergen Drug Corp for RINVOQ ER 15 mg tablets (30-count units) on August 19, 2025, with completion scheduled for August 20, 2025. This firm fixed price, competitively awarded contract represents a small-value transaction within AmerisourceBergen's extensive pharmaceutical supply portfolio supporting federal medical procurement. The award is issued as a child contract under AmerisourceBergen's...
- The Defense Logistics Agency (DLA) awarded a delivery order valued at $5,015.55 to AmerisourceBergen Drug Corp for RINVOQ ER 15 mg tablets (30-count unit of use packaging) on August 22, 2025, with an ultimate completion date of August 25, 2025. This firm fixed-price, non-set-aside delivery order was competitively awarded and will be performed at the contractor's facility in Conshohocken, Pennsylvania. The award represents a single transaction under AmerisourceBergen's larger indefinite...
- The Defense Logistics Agency awarded a delivery order valued at $39,491.47 to AmerisourceBergen Drug Corp for RINVOQ ER 45 mg tablets (28-count units) on August 8, 2025, with an ultimate completion date of August 11, 2025. This firm fixed-price delivery order was competitively awarded with no set-aside designation. The pharmaceutical product will be delivered to the company's corporate office location in Conshohocken, Pennsylvania. This delivery order is issued under AmerisourceBergen Drug...
- The Defense Logistics Agency (DLA) awarded a $21,909.46 delivery order to AmerisourceBergen Drug Corp for RINVOQ ER 30 mg tablets (30-count units) on August 20, 2025, with an ultimate completion date of August 21, 2025. This competitively awarded, firm fixed-price delivery order carries no set-aside designation and will be performed at AmerisourceBergen's corporate office location in Conshohocken, Pennsylvania. The contract represents a child order under AmerisourceBergen's larger Indefinite...
- The Defense Logistics Agency (DLA) awarded a delivery order valued at $22,172.92 to AmerisourceBergen Drug Corp for RINVOQ ER 15 mg tablets (30-count units) on August 20, 2025, with ultimate completion by August 21, 2025. This competitively awarded, firm fixed-price delivery order carries no set-aside designation and will be performed at the vendor's corporate office location in Conshohocken, Pennsylvania. The award represents a child contract under AmerisourceBergen's larger Indefinite Delivery...
- The Defense Logistics Agency awarded a delivery order valued at $37,112.83 to AmerisourceBergen Drug Corp for RINVOQ ER 45 mg tablets (28-tablet units) on July 21, 2025, with an ultimate completion date of July 22, 2025. This firm fixed-price, non-set-aside delivery order represents a child contract under AmerisourceBergen's larger Indefinite Delivery Contract (IDC) with DLA Troop Support Medical, designated SPE2DX and valued at $999,999,999.00 through December 2026. The contract is being...
- The Defense Logistics Agency awarded a delivery order valued at $9,188.42 to AmerisourceBergen Drug Corp for RINVOQ ER 30 mg tablets (30-count units) on August 15, 2025, with an ultimate completion date of August 18, 2025. This firm fixed price contract utilizes no set-aside designation and represents a competitive award under the company's existing Indefinite Delivery Contract (IDC) with DLA Troop Support Medical (SPE2DX), a $999,999,999.00 global pharmaceutical support vehicle running...
- SPE2DB24D2105Indefinite Delivery Contract
- SPE2DB24D2105-SPE2DB25FAQCUDelivery Order
The Defense Logistics Agency (DLA) awarded a delivery order valued at $39,043.38 to AmerisourceBergen Drug Corp for RINVOQ ER 45 mg tablets (28-count units) on August 21, 2025, with a completion date of August 22, 2025. This firm fixed-price delivery order represents a non-set-aside competitive award and leverages AmerisourceBergen's existing Indefinite Delivery Contract (IDC) with DLA Troop Support Medical (designated SPE2DX), which carries a $999,999,999.00 potential value through December 2026. The place of performance is AmerisourceBergen's corporate office in Conshohocken, Pennsylvania. AmerisourceBergen Drug Corp serves as a major pharmaceutical distributor for federal military and veteran healthcare systems, supplying a comprehensive portfolio of brand-name and generic medications, vaccines, and medical supplies across multiple therapeutic domains. The DLA Troop Support Medical IDC serves as a flexible contract vehicle enabling AmerisourceBergen to deliver critical pharmaceutical products to support military healthcare programs globally, including service to the Defense Health Agency and U.S. Coast Guard. This delivery order for RINVOQ ER, a specialty medication, exemplifies the company's role as a key vendor within the federal medical supply chain and reflects the DLA's continued reliance on AmerisourceBergen's capabilities to meet pharmaceutical procurement requirements.
Mod # | Description | ReasonForModification | Federal Obligation | Date |
|---|---|---|---|---|
| Not listed | Not listed | $39.0k | 8/21/25 |